<DOC>
	<DOCNO>NCT00006363</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PSC 833 may increase effectiveness chemotherapy make cancer cell sensitive drug . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . This randomized phase III trial study give combination chemotherapy together PSC 833 follow peripheral stem cell transplant without interleukin-2 see well work compare combination chemotherapy alone follow peripheral stem cell transplant without interleukin-2 treating patient acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without PSC 833 , Peripheral Stem Cell Transplantation , and/or Interleukin-2 Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether addition PSC-833 ( valspodar ) induction chemotherapy improve disease-free survival overall survival patient acute myeloid leukemia ( AML ) &lt; 60 year . II . To determine whether post-consolidation immunotherapy low-dose continuous/intermittent high-dose bolus subcutaneous recombinant interleukin-2 ( rIL-2 ) ( aldesleukin ) improve disease-free survival overall survival patient AML &lt; 60 year first complete remission ( CR ) . SECONDARY OBJECTIVES : I . To continue evaluate effectiveness three course high-dose ARA-C ( HiDAC ) ( cytarabine ) curative consolidation chemotherapy patient core bind factor ( CBF ) leukemia . II . To continue establish use intensive post-remission chemotherapy PSCT novel intensification sequence consist HiDAC/high-dose etoposide/G-CSF ( filgrastim ) follow two cycle HiDAC patient CR unfavorable cytogenetics . III . To correlate rate relapse toxicity busulfan pharmacokinetics busulfan etoposide use prior autologous stem cell transplantation AML patient first CR . OUTLINE : This randomize , multicenter study . INDUCTION THERAPY : Patients randomize 1 2 treatment arm . ARM I : Patients receive cytarabine IV continuously day 1-7 daunorubicin IV 5-10 minute follow etoposide IV 2 hour day 1-3 . Patients 20 % great bone marrow cellularity great 5 % leukemia blast end first course receive second course cytarabine IV continuously day 1-5 daunorubicin IV 5-10 minute follow etoposide IV 2 hour day 1 2 . ARM II : Patients receive PSC 833 IV continuously day 1-3 cytarabine , daunorubicin , etoposide arm I . Patients 20 % great bone marrow cellularity great 5 % leukemia blast end first course receive second course PSC 833 IV continuously day 1 2 cytarabine , daunorubicin , etoposide arm I. INTENSIFICATION THERAPY : Patients complete remission receive intensification therapy . Therapy begin early 2 week later 4 week complete remission attain . Patients stratify accord cytogenetics ( favorable [ ( 8 ; 21 ) ( q22 ; q22 ) inv ( 16 ) ( p13 ; q22 ) ( 16 ; 16 ) ( p13 ; q22 ) ] vs unfavorable [ karyotype ] ) . FAVORABLE : Patients receive high-dose cytarabine ( HiDAC ) IV 3 hour every 12 hour day 1 , 3 , 5 . Treatment repeat early 28 day prior course later 14 day hematopoietic recovery two course . UNFAVORABLE : Patients divide two group base ability receive peripheral blood stem cell transplantation ( PBSCT ) ( yes v ) . PBSCT GROUP : Patients receive etoposide IV continuously HiDAC IV 2 hour every 12 hour day 1-4 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 14 continue peripheral blood stem cell ( PBSC ) collection complete . Patients able undergo PBSCT HiDAC/etoposide continue treatment non-PBSCT group . At least 4 week HiDAC/etoposide recovery , patient receive oral busulfan every 6 hour day -7 -4 etoposide IV 4 hour day -3 prior PBSCT . Patients receive autologous PBSC infusion day 0 . Patients also receive G-CSF SC begin day 0 continue hematopoietic recovery . NON-PBSCT GROUP : Patients receive etoposide , HiDAC , G-CSF PBSCT group . After hematopoietic recovery , patient receive HiDAC IV 3 hour every 12 hour day 1 , 3 , 5 . Treatment repeat early 28 day prior course later 14 day hematopoietic recovery one course . IMMUNOTHERAPY : Patients randomize 1 2 treatment arm . ARM I : Patients begin therapy later 120 day first day last course HiDAC treatment OR day 0 PBSCT . Patients receive low-dose interleukin-2 ( IL-2 ) SC day 1-14 , 19-28 , 33-42 , 47-56 , 61-70 , 75-90 . In addition , patient receive high-dose IL-2 SC day 15-17 , 29-31 , 43-45 , 57-59 , 71-73 . ARM II : Patients observe receive therapy . Patients follow 1 month , every 2 month 2 year , every 6 month 2 year , annually 6 year . PROJECTED ACCRUAL : A total 720 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Unequivocal histologic diagnosis AML ( &gt; 20 % blast bone marrow base World Health Organization [ WHO ] and/or FrenchAmericanBritish Cooperative group [ FAB ] classification ) , exclude M3 ( acute promyelocytic leukemia ) ; patient antecedent myelodysplasia eligible treatment trial bone marrow biopsy show myelodysplastic syndrome ( MDS ) &gt; 3 month prior enrollment ; patient therapyrelated MDS therapyrelated AML chronic myeloproliferative disorder eligible No prior treatment leukemia myelodysplasia four permissible exception : Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea Cranial radiation therapy ( RT ) central nervous system ( CNS ) leukostasis ( one dose ) Growth factor/cytokine support</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>